Switzerland approved Ronapreve by COVID-19

The Swiss regulator approved Ronapreve developed by Roche and Regeneron. The antibody-based drug is indicated for the treatment of COVID-19. At the time of the decision, no data were available on the efficacy of Ronapreve against the Omicron strain.